Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFTER trial in adult women with acne vulgaris
2025-520773-39-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acne vulgaris comparing Low-dose isotretinoin attack phase with Spironolactone attack phase (2 arms). Primary endpoint: GEA score at month 6. Planned start Oct 2026; status: authorised.
02
Drugs
isotretinoinspironolactone
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on 2025-520773-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520773-39-00.